Skip to content
OpenCapital
Get started

Vaxcyte, Inc. PCVX AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Fair Value

AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Fair Value at other companies

Moderna logo
ModernaMRNA
——
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
——

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$7.43B+72.0%
Enterprise value$7.28B+78.6%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0×0.0×
Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s afs and trading securities - unrealized loss position (>=12 months) fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vaxcyte, Inc.'s AFS and trading securities - unrealized loss position (>=12 months) fair value?
Vaxcyte, Inc. (PCVX) reported AFS and trading securities - unrealized loss position (>=12 months) fair value of $491.9M in Q1 2026.
How has Vaxcyte, Inc.'s AFS and trading securities - unrealized loss position (>=12 months) fair value changed year-over-year?
Vaxcyte, Inc.'s AFS and trading securities - unrealized loss position (>=12 months) fair value increased by 8381.0% year-over-year, from $5.8M to $491.9M.